Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
23-25 May, 2025
Not Confirmed
Not Confirmed
26-27 May, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
23-25 May, 2025
Industry Trade Show
Not Confirmed
26-27 May, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/us-drug-shortages-reduce-16-yoy-in-q1-2025-cns-drugs-antimicrobials-face-highest-scarcities
20 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-announces-first-participants-dosed-in-a-us-clinical-study-combining-adipose-targeted-once-monthly-injectable-small-molecule-thr-agonist-asc47-and-semaglutide-for-the-treatment-of-obesity-302460251.html
06 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-announces-oral-and-poster-presentations-on-asc47-an-adipose-targeted-muscle-preserving-weight-loss-drug-candidate-for-obesity-at-the-32nd-european-congress-on-obesity-302446777.html
23 Apr 2025
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/ascletis-sees-no-benefit-high-fast-oral-glp-1-dose-titration-takes-low-slow-regimen-forward
22 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-announces-positive-topline-results-of-us-phase-ib-multiple-ascending-dose-study-of-small-molecule-oral-glp-1r-agonist-asc30-and-submission-of-13-week-phase-iia-study-protocol-to-fda-302434655.html
31 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-announces-positive-interim-results-from-its-us-phase-ib-trial-with-asc30-a-potentially-first-in-class-subcutaneous-injection-small-molecule-glp-1r-agonist-302415466.html
26 Mar 2025
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/ascletis-goes-all-metabolic-disease-slashing-former-core-programs-wholesale-pivot-obesity
ABOUT THIS PAGE